key: cord-0859270-f5au9fiy
authors: Bastard, Paul; Zhang, Qian; Zhang, Shen-Ying; Jouanguy, Emmanuelle; Casanova, Jean-Laurent
title: Type I interferons and SARS-CoV-2: from cells to organisms
date: 2022-01-25
journal: Curr Opin Immunol
DOI: 10.1016/j.coi.2022.01.003
sha: 3583b6e73dc5989a6cbd4b4cec6b6605499c6ebb
doc_id: 859270
cord_uid: f5au9fiy

Type I interferons (IFNs) have broad and potent antiviral activity. We review the interplay between type I IFNs and SARS-CoV-2. Human cells infected with SARS-CoV-2 in vitro produce low levels of type I IFNs, and SARS-CoV-2 proteins can inhibit various steps in type I IFN production and response. Exogenous type I IFNs inhibit viral growth in vitro. In various animal species infected in vivo, type I IFN deficiencies underlie higher viral loads and more severe disease than in control animals. The early administration of exogenous type I IFNs improves infection control. In humans, inborn errors of, and auto-antibodies against type I IFNs underlie life-threatening COVID-19 pneumonia. Overall, type I IFNs are essential for host defense against SARS-CoV-2 in individual cells and whole organisms.

Humans have co-evolved with various viruses, with infinite interactions selecting both human and viral variants [1] . Most human-tropic viruses currently cause life-threatening disease in only a minority of infected individuals, but a few such viruses have caused major pandemics [2, 3] . December 2019 saw the start of a pandemic of coronavirus disease 19 (COVID-19) [4] , caused by a new virus, severe respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus rapidly spread worldwide, causing the deadliest pandemic of a viral respiratory disease since the 'Spanish Flu' in 1918. Most infected individuals are asymptomatic or have mild flu-like clinical manifestations, but about 20% suffer pneumonia. Non-hypoxemic 'moderate' pneumonia rarely requires hospitalization and is seen in about half these cases, whereas the other half experience hypoxemic pneumonia, typically requiring hospital admission for oxygen therapy. It is thought that between 400 million and 1 billion people have been infected. More than 4 million people have died from COVID-19 [5] , with some estimates placing the true figure closer to 7-9 million. The estimated infection fatality rate (IFR) in J o u r n a l P r e -p r o o f unvaccinated individuals is about 1%. Age is the major epidemiological risk factor for hospitalization or death from pneumonia, the risk doubling with every five years of age from childhood onward [6] [7] [8] . The risk is 10,000 times greater at the age of 85 years (10%) than at the age of five years (0.001%). Other epidemiological risk factors have been described, but with much lower odds ratios (ORs), almost always <2 [9,10].

SARS-CoV-2 is an enveloped, positive-sense single-stranded RNA virus from the Coronaviridae family [11] . Seven coronaviruses are known to infect humans, four of which are endemic (2 alphaviruses: 229E and NL63; 2 betaviruses: OC43 and HKU1), the other three being epidemic or pandemic betacoronaviruses: SARS-CoV, MERS-CoV, and SARS-CoV-2.

These last three viruses are the most virulent, with an IFR due to pulmonary disease at least 1,000 times greater than that for the endemic coronaviruses. SARS-CoV-2 expresses four structural proteins -S (spike), E (envelope), M (membrane), and N (nucleocapsid) -16 nonstructural proteins (Nsp1-16), and nine accessory proteins (ORF3a, 3b,6, 7a, 7b, 8, 9b, 9c and 10) [12] . SARS-CoV-2 can enter many cell types, but can replicate in human cells only after entry involving interaction between its S protein and angiotensin-converting enzyme 2 (ACE2).

ACE2 is the main receptor of the virus and is expressed principally by ciliated epithelial cells in the nasal cavity, type II pneumocytes and ciliated cells in the respiratory tract, together with cells in the small intestine, testis, kidney, heart muscle, colon, and thyroid gland. TMPRSS2 is a coreceptor of SARS-CoV-2 with a potential role in priming, through cleavage of the S protein;

it is also expressed in respiratory cells [13] [14] [15] . Although the suspected natural hosts of SARS-CoV-2 include bats and pangolins [16] , the origin of transmission from wildlife to humans is currently debated [17] [18] [19] .

Type I interferons (IFNs) were described by Isaacs and Lindenman in 1956 [20] , and act to fend off viruses in most, if not all jawed vertebrates [21, 22] . Their evolution attests to both J o u r n a l P r e -p r o o f strong negative selection across species and a surprising degree of diversity within each species [23] . There are 17 subtypes of type I IFNs in humans, encoded by 17 intron-less genes:   13 IFN- subtypes, IFN-, IFN-β, IFN-ε, and IFN-κ, all of which bind to the same heterodimeric receptor (IFNAR1 and IFNAR2) [24] . IFN-β is induced by viruses in most cell types, and can then induce the other type I IFNs, whereas IFN- and IFN- are produced principally by leukocytes [1, 25] , and IFN-ε, and IFN-κ are constitutively expressed but also induced in the female reproductive tract and skin, respectively [26, 27] . Excessive type I IFN activity is deleterious in humans, as shown by type I interferonopathies [28] . Conversely, inborn deficiencies of type I IFN immunity underlie various viral illnesses, including adverse events following vaccination with live-attenuated viruses (measles-mumps-rubella and yellow fever), severe or recurrent VZV infection, severe influenza pneumonia, and herpes simplex virus encephalitis [29] . These observations suggest that the levels of type I IFNs must be tightly regulated, both at baseline and during viral infection. Many viral products inhibiting the induction of or response to human type I IFNs have been described [30] [31] [32] [33] [34] [35] . We review here the interplay between SARS-CoV-2 and type I IFNs, both in vitro and in vivo, in animals and in humans.

The infection of human cells with SARS-CoV-2 in vitro induces type I IFNs (Fig. 1) . These molecules are produced following the recognition of viral intermediates or their by-products by microbial sensors. Mitochondrial antiviral signaling protein (MAVS) is activated by the sensing of SARS-CoV-2 RNA in the cytosol of human lung epithelial cell lines (A549, Calu-3) by melanoma differentiation-associated gene 5 (MDA5) and RNA helicase retinoic acid-inducible gene I (RIG-I) [36] [37] [38] [39] . Endosomal receptors have also been implicated in this process in the same cells. Indeed, SARS-CoV-2 can activate IRF3 via TICAM1 following sensing by TLR3, and J o u r n a l P r e -p r o o f NF-κB via MyD88 after sensing by TLR7 [24, 40] . TLR3 and TLR7 have been shown to sense SARS-CoV-2 in Calu-3/Medical Research Council cell strain 5 (MRC-5) [41] . In addition, TLR7 and TLR8 may activate plasmacytoid dendritic (pDCs) cells following infection [42] . The activation of these three pathways leads to the activation of IFN-regulatory factors 3 and 7 (IRF3, IRF7) and NF-κB, resulting in the production of type I IFNs, by pDCs, for example [43] .

These type I IFNs then induce the expression of interferon-stimulated genes (ISGs) [44] [45] [46] .

Induction levels range from low to high, depending on the cells studied. Interestingly, other viruses, such as seasonal influenza A viruses (IAV) [47] and Sendai virus (SeV) [30] , induce type I IFNs more strongly than SARS-CoV-2. The three epidemic coronaviruses induce much lower levels of type I IFNs than common coronaviruses, which generally cause benign infections, suggesting that the capacity to diminish type I IFN induction is a key component of their virulence [30] [31] [32] [33] .

SARS-CoV-2 is a poor inducer of type I IFNs, not only because it inhibits core cellular functions, such as transcription and translation [48] , but also because it specifically inhibits various molecules involved in type I IFN production. About half the 29 known viral proteins target human proteins in the type I IFN induction pathways, including IRF3, NEMO, TBK1, MAVS and RIG-I, and/or in the type I response pathway, including IFNB self-amplification [49] [50] [51] [52] [53] . The viral proteins involved include Nsp1, Nsp5, Nsp6, Nsp13, Nsp14, Nsp15, ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF9b, M, and N. Several unbiased screens have shown that both type I IFN production and ISG induction can be inhibited by ORF6 [54] . The production of, and response to type I IFNs can also be inhibited by Nsp1, via inhibition of the association of IRF3 with the IFNB promoter, of protein translation [55] [56] [57] , and via the blocking of mRNA J o u r n a l P r e -p r o o f access to ribosomes [58] . The nuclear translocation of ISGF3, the key transducer of the type I IFN response, can be inhibited by ORF3b [59] . One variant of SARS-CoV-2 displays an even stronger inhibitory effect, due to its production of a longer ORF3b. Interestingly, the cleavage of ISG15 from IRF3 is promoted by Nsp3, leading to an attenuated IFN response [60] . The induction of lower levels of endogenous IFN-β has also been reported for an ORF7b variant [55] . Nsp14 can shut down translation, by impairing the type I IFN-dependent induction of ISGs [61] . MERS-CoV and SARS-CoV have also developed approaches for evading type I IFNs [62] . Other molecules have been shown to inhibit the type I IFN pathway in different experimental settings (such as overexpression and knockout), further suggesting a major role of type I IFNs in the anti-SARS-CoV-2 response [22] .

SARS-CoV-2 is highly sensitive to pretreatment with type I IFNs [50, 63, 64] . Exogenous type I IFN does not seem to be inhibited by the virus [55, 65, 66] . The impact of treatment with type I and type III IFNs on the intracellular growth of various viral strains has been evaluated.

Concentrations of type I IFNs in the pg/mL range can inhibit SARS-CoV-2 replication in various cells [67] [68] [69] . Recent variants, such as B.1, B.1.1.7 (alpha), and B.1.1351 (beta), can resist concentrations of type I and III IFNs 25 to 322 times higher than those effective against earlier strains, such as strains A and B [70] . The virus becoming more resistant to anti-viral mechanisms, such as type I IFNs, may in principle increase its fitness or its virulence. In addition to these studies of the impact of exogenous type I IFNs, genome-or proteome-wide screens have been performed to identify other host factors for which an absence leads to higher levels of SARS-CoV-2 replication, and host proteins capable of interacting with viral proteins [71] [72] [73] [74] [75] . Some of these factors interact with SARS-CoV-2 and other coronaviruses (for J o u r n a l P r e -p r o o f example, HMGB1 and proteins related to cholesterol metabolism), whereas others, such as Rab GTPase, interact specifically with SARS-CoV-2 [72, 73] . These studies let to the identification of therapeutic options, including exogenous type I IFNs which could be tested and validated by future work.

Studies have also been performed in animals in vivo, including species that are naturally susceptible to SARS-CoV-2 [50, 76, 77] . In hamsters, SARS-CoV-2 infection triggers an ISG signature in the lungs [78] [79] [80] . In ferrets, the ISG signature triggered by SARS-CoV-2 and detected in respiratory swab samples is weaker than that observed after IAV infection [47] . In non-human primates, SARS-CoV-2 infection triggers a stronger induction of type I IFNs in the lungs when comparing to IAV [81, 82] . The interspecies variability of type I IFN induction may reflect differences between the animal species used, the viral inoculum [78] , the age of the animals [83] , and the stage of infection studied [50] . These animals are naturally susceptible to SARS-CoV-2 infection, but it is, nevertheless, difficult to extrapolate these findings to humans, because viral proteins may block animal and human proteins involved in type I IFN immunity differently. Interestingly, Stat2 -/-(lacking both type I and III IFN responses) hamsters fail to control SARS-CoV-2 infection, whereas this infection is successfully controlled by Il-28r -/-(deficient for the type III IFN response only) animals [84] . Moreover, intranasal treatment with universal IFN- within one to three days of infection can protect hamsters from severe disease [85, 86] .

Mice are less physiologically and pathologically relevant in this context, as they are not naturally susceptible to SARS-CoV-2 infection. Transgenic mice expressing human ACE2 (hACE2) under the control of the cytokeratin 18 (KRT18) promoter predominantly in epithelial cells are susceptible to SARS-CoV-2 [87] . Type I IFN induction was detected in the lungs of SARS-CoV-2-infected K18-hACE2 mice, which developed severe lung damage [88, 89] . Mice transduced intranasally with replication-defective adenoviruses encoding hACE2 can be infected at peak hACE2 expression [90, 91] . In this model, SARS-CoV-2 infection is self-limited due to the transient nature of hACE2 expression. Nevertheless, two days after SARS-CoV-2 infection, an absence of type I IFN induction was observed in Ifnar1 -/and Irf3 -/-Irf7 -/mice, although these mice did not display a poorer control of viral replication [91] . Consistently, mice lacking both type I and II IFN receptors (IFNR-DKO) infected with a SARS-CoV-2 strain genetically adapted to the mouse ACE2 (SARS-CoV-2 MA) display enhanced susceptibility to the virus [92] . Finally, the administration of the type III interferon IFN-λ1 decreased SARS-CoV-2 replication in wild-type mice; the effects of type I IFNs were not investigated [93] . Overall, endogenous and exogenous type I IFNs have been reported to exert antiviral activity against SARS-CoV-2 in most animal studied in vivo. Extrapolation of these findings to humans is however difficult.

Patients with inborn errors (IE) of type I IFN immunity affecting either IFN production or the response to IFNs have been shown to suffer from severe viral infections in childhood or early adulthood [29] . Interestingly, three inborn errors of immunity (IEI) -deficiencies of IRF7, IRF9 and TLR3 -have been shown to underlie life-threatening influenza pneumonia [94] [95] [96] . The COVID Human Genetic Effort (CHGE) (www.covidhge.com) tested the hypothesis that Three young children carried the genotype but presented only mild infection [99] . The cumulative MAF of deleterious TLR7 variants reported in a public database (gnomAD) was 6.5x10 -4 in men, and only half (4/8) the TLR7 variants reported by other groups were found to be deleterious [100] [101] [102] [103] . Interestingly, endosomal TLR7 had long been known to sense ssRNA [104] , and its gene as known to be under strong negative selection [105] , but its role in host defense in humans had remained unclear. These new studies demonstrate that pDCs, which constitutively express both TLR7 and IRF7, are crucial for host defense against SARS-CoV-2, due to their production of type I IFNs [46, 106] . Remarkably, TLR3 is expressed by respiratory J o u r n a l P r e -p r o o f epithelial cells, whereas TLR7 is not [96, 107] . Overall, TLR3-and TLR7-dependent type I IFN immunity in PECs and pDCs, respectively, is crucial for defense against SARS-CoV-2.

Auto-Abs against type I IFN were first reported in the 1980s, in patients treated with type I IFNs and in patients with systemic lupus erythematosus (SLE) [108, 109] . They were widely thought to have no impact on antiviral immunity. However, the COVID-HGE showed in 2020 that at least 10% of individuals with critical COVID-19 and without type I IFN inborn errors had auto-Abs neutralizing supraphysiological concentrations (10 ng/mL in plasma diluted 1/10) of IFN-2 and/or IFN- [110] . In addition, APS-1 patients, who display these auto-Abs from infancy onward, are at very high risk of developing severe or critical COVID-19 pneumonia [111, 112] . These auto-Abs were present before infection in the few cases tested, suggesting they were not induced by the virus. Moreover, these auto-Abs to type I IFNs were not found in patients with asymptomatic or mild SARS-CoV-2 infection. These findings were later replicated in various regions [113] [114] [115] [116] [117] [118] [119] [120] [121] . Longitudinal profiling studies of over 600,000 peripheral blood mononuclear cells from patients with or without auto-Abs neutralizing type I IFNs described in depth the consequences of these auto-Abs, reporting a lack of ISGs in myeloid cells [118] . Unbiased auto-Ab screening assays also identified other auto-Abs triggered by the virus [117, 122] .

Physiological concentrations of type I IFNs in COVID-19 patients range between 1 and 100 pg/mL in plasma. At least 13.6% of the patients with critical COVID-19 had auto-Abs neutralizing 100 pg/mL IFN-2 and/or IFN-, and this proportion was higher (20%) in the J o u r n a l P r e -p r o o f elderly and in individuals who died from COVID-19 [67] . Auto-Abs neutralizing IFN-β were found in about 1% of patients with critical COVID-19 with no other anti-type I IFN auto-Abs. In addition, 6.8% of patients with severe (but not critical) COVID-19 carried neutralizing auto-Abs. We estimated the ORs by comparing the prevalence of auto-Abs in patients with critical disease with those in patients with asymptomatic or mild infection (Figure 2 ) [67] . The highest ORs were those for patients with auto-Abs neutralizing both IFN-2 and IFN-, at 10 ng/mL and 100 pg/mL (67, P < 7.8x10 -13 for 10 ng/mL,and 54, P < 10 -13 for 100 pg/mL; Figure 2 ). The

ORs for auto-Abs against IFN-2 and/or IFN-, or against IFN- only, were lower, but still highly significant. For auto-Abs against IFN-β only, the ORs for critical disease were lower, at 5 (P = 0.043). These observations suggest that deficiencies of single type I IFNs can underlie life-threatening COVID-19 pneumonia, albeit with incomplete penetrance.

These auto-Abs were found to be present in about 0.3% of the few thousand individuals under the age of 65 years tested [110, 118] . In a sample of more than 34,000 uninfected individuals aged 18 to 100 years, the prevalence of auto-Abs neutralizing 10 ng/mL (and 100 pg/mL) of IFN-2 or IFN- increased significantly with age, with 0.17% (1.1%) of individuals positive for these antibodies under the age of 70 years, and more than 1.4% (4.4%) positive over the age of 70 years, consistent with the higher risk of life-threatening and lethal COVID-19 in the elderly population [67] . Patients under the age of 18 years were not tested, and no tests were performed for auto-Abs neutralizing IFN-ε or IFN-κ. Conversely, auto-Abs neutralizing IFN-β were found to have the same prevalence in all age categories tested. These findings are related to the enigmatic presence of 17 individual type I IFNs in humans, all of which bind to the same receptors [23, 24] . The 13 forms of IFN- and IFN- are secreted by J o u r n a l P r e -p r o o f leukocytes and are very closely related biochemically and phylogenetically, whereas IFN-β, IFN-ε, and IFN-κ are more distantly related and have specific functions [26, 27] . Interestingly, patients with severe COVID-19 and auto-Abs against type I IFNs displayed impaired ISG induction remain silent, until an emergent virus, such as SARS-CoV-2, reveals the deficiency with life-threatening pneumonia.

The impact of effective or defective type I IFN immunity has been studied in several tissues. First, like other coronaviruses, SARS-CoV-2 infects humans via the upper respiratory tract. The impact of IFNs in the upper respiratory tract was therefore assessed by RNA-seq in a cohort of 58 individuals, including 14 with mild COVID-19 and 21 with severe COVID-19 [123] .

The patients with mild COVID-19 presented a robust type I IFN response, whereas those with severe COVID-19 did not. Conversely, impaired local intrinsic immunity to COVID-19 was associated with high levels of type I IFNs and low levels of type III IFNs (except for IFN-λ2) in the upper and lower respiratory tract, with low levels of ISG expression [124] . Auto-Abs against type I IFNs were found in one of eight patients tested with severe COVID-19, and were associated with impaired local type I IFN immunity [124] . Auto-Abs against type I IFNs were detected in tracheal aspirates and in nasal swabs from COVID-19 patients with circulating auto-Abs [69, 125] . Interestingly, patients with severe COVID-19 and auto-Abs against type I IFNs displayed impaired ISG induction in nasal mucosa [69] ; while the impact of these antibodies in the lower respiratory tract is unknown. Overall, these findings suggest a strong antiviral effect of type I IFNs on SARS-CoV-2 in the upper respiratory tract, which can be blocked by auto-Abs neutralizing these type I IFNs [126] . PubMed. Many more studies will be published. What has emerged from the study of COVID-19 is that the pathogenesis of the life-threatening pneumonia it causes revolves around deficiencies of type I IFN immunity [127, 128] . The identification of both patients with genetic deficiencies of type I IFNs and other patients with pre-existing auto-Abs neutralizing type I IFNs has shown that a single unifying mechanism can explain almost a fifth of critical cases.

This proportion of mechanistically and causally explained cases is unprecedented among common human infectious diseases [129, 130] . Along with the in vitro studies showing that SARS-CoV-2 can inhibit type I IFN induction in numerous ways, these findings indicate that a key virulence factor of SARS-CoV-2 -possibly even its principal virulence factor -is its ability to suppress the induction and action of type I IFNs [131] . These findings also suggest that the administration of exogenous type I IFNs (for example IFN-β) early in the course of infection (i.e. before the inflammatory phase) [132] might be beneficial in some patients, such as those with defects of type I IFN production, those with auto-Abs against IFN-, IFN- but not IFN-β, and individuals at risk (such as elderly individuals). In infected and unvaccinated patients unresponsive to type I IFN, mAbs neutralizing the virus should be administered promptly, as recently shown for an IRF9-deficient patient [133] . Patients with insufficient type I IFN immunity should be vaccinated as a matter of priority and their levels of protective Abs against SARS-CoV-2 monitored to determine the frequency with which vaccination boosters should be delivered, and patients hospitalized for breakthrough infections should also be studied for both Abs developed in response to the vaccine and type I IFN deficiencies. 

Abs against type I IFNs. Odds ratios (OR) and P-values were estimated by means of Firth's bias-corrected logistic regression.

Interferons and viruses: an evolutionary arms race of molecular interactions

History of Smallpox and Its Spread in Human Populations. Microbiol Spectr

Here a virus, there a virus, everywhere the same virus?

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Worldometer: COVID-19 CORONAVIRUS PANDEMIC

Assessing the age specificity of infection fatality rates for COVID

Cross-Species Genome-Wide Analysis Reveals Molecular and Functional Diversity of the Unconventional Interferon-omega Subtype

Type I and III interferon responses in SARS-CoV-2 infection

*Comprehensive review of type I and III interferons and SARS-CoV-2. The authors detail the known type I IFN inhibitory mechanisms by SARS-CoV-2

Evolutionary genetic dissection of human interferons

Shared and Distinct Functions of Type I and Type III Interferons

Production of type I interferons: plasmacytoid dendritic cells and beyond

Properties and Functions of the Novel Type I Interferon Epsilon

Interferon-kappa, a novel type I interferon expressed in human keratinocytes

The type I interferonopathies: 10 years on

Viral infections in humans and mice with genetic deficiencies of the type I IFN response pathway

Activation and evasion of type I interferon responses by SARS-CoV-2

Decoding type I and III interferon signalling during viral infection

Type I and Type III Interferons -Induction, Signaling, Evasion, and Application to Combat COVID-19

Evasion of Type I Interferon by SARS-CoV-2

A: Ten Strategies of Interferon Evasion by Viruses

Innate Immune Evasion by Human Respiratory RNA Viruses

The RNA sensor MDA5 detects SARS-CoV-2 infection

RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells

Report that RIG-I can restrict SARS-CoV-2 infection in a type I and III IFN-dependent manner

The NF-kappaB transcriptional footprint is essential for SARS-CoV-2 replication

SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation

A: Type I interferons in infectious disease

TLR3 and TLR7 RNA Sensor Activation during SARS-CoV-2 Infection. Microorganisms 2021

Report that TLR3 and TLR7 are important in Calu-3/MRC-5 cells to induce type I IFNs

SARS-CoV-2-associated ssRNAs activate inflammation and immunity via TLR7/8

SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4

Type I Interferon Induction and Exhaustion during Viral Infection: Plasmacytoid Dendritic Cells and Emerging COVID-19 Findings. Viruses 2021

SARS-CoV-2 Isolates Show Impaired Replication in Human Immune Cells but Differential Ability to Replicate and Induce Innate Immunity in

Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Report of patients with COVID-19, low type I and III IFN production and high chemokine and IL-6 expression

SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses

Type I Interferons in COVID-19 Pathogenesis

Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19

Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be

SARS-CoV-2 Disrupts Proximal Elements in the JAK-STAT Pathway

SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling

Type I Interferons in COVID-19 Pathogenesis

SARS-CoV-2 suppresses IFNbeta production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon

SARS-CoV-2 Nonstructural Protein 1 Inhibits the Interferon Response by Causing Depletion of Key Host Signaling Factors

Genomic monitoring of SARS-CoV-2 uncovers an Nsp1 deletion variant that modulates type I interferon response

Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2

SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV

Human Nasal and Lung Tissues Infected Ex Vivo with SARS-CoV-2 Provide Insights into Differential Tissue-Specific and Virus-Specific Innate Immune Responses in the Upper and Lower Respiratory Tract

Inhibition of SARS-CoV-2 by type I and type III interferons

Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

Report that auto-Abs neutralizing low concentrations of type I IFNs can account for about 15% of life-threatening cases. The prevalence of these auto-Abs increases with age in the uninfected population

Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine

Report that auto-Abs to type I IFNs can underlie severe adverse reactions to the yellowfever live attenuated virus vaccine

Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs

Report that auto-Abs to type I IFNs are present and functional in the upper respiratory tract

Interferon Resistance of Emerging SARS-CoV-2 Variants

Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells

Report of CRISPR screens identifying cellular factors important for SARS-CoV-2 entry

Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms

Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors

Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks

Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses

Report of CRISPR screens identifying cellular factors important for SARS-CoV-2 entry

Animal models of SARS-CoV-2 transmission

Animal models for COVID-19

*Review of animal models of SARS-CoV-2 infection

Kinetic multi-omic analysis of responses to SARS-CoV-2 infection in a model of severe COVID-19

SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and nonrespiratory tissues including the heart and kidney

Temporal omics analysis in Syrian hamsters unravel cellular effector responses to moderate COVID-19

Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

SARS-CoV-2 infection induces protective immunity and limits transmission in Syrian hamsters

STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters

Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model

Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice

COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice

A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies

Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling

A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency

Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency

Severe influenza pneumonitis in children with inherited TLR3 deficiency

Inborn errors of type I IFN immunity in patients with lifethreatening COVID-19

report that inborn errors of type I IFN immunity can underlie life-threatening COVID-19 pneumonia. Surprisingly, four unrelated adults had complete IFNAR1 or IRF7 deficiency

Severe COVID-19 in the young and healthy: monogenic inborn errors of immunity?

X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19

Report that X-linked recessive TLR7 deficiency impairs production of type I IFNs by pDCs and underlies at least 1% of cases of life-threatening COVID-19 pneumonia in men

Association of rare predicted loss-of-function variants of influenza-related type I IFN genes with critical COVID-19 pneumonia

Presence of Genetic Variants Among Young Men With Severe COVID-19

Association of Toll-like receptor 7 variants with lifethreatening COVID-19 disease in males: findings from a nested case-control study

Case report: hepatitis in a child infected with SARS-CoV-2 presenting toll-like receptor 7 Gln11Leu single nucleotide polymorphism

Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses

Evolutionary dynamics of human Toll-like receptors and their different contributions to host defense

Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19

X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19

Niethammer D: Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon

Antibodies to alpha-interferon in a patient with systemic lupus erythematosus

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

report that auto-Abs neutralizing high concentrations of type I IFNs underlie at least 10% of cases of life-threatening COVID-19 pneumonia

Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1

Report of an international cohort of APS-1 patients, harboring auto-Abs to type I IFNs since early childhood, most of whom developed life-threatening COVID-19 pneumonia

Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1

Report of four German APS-1 patients, who did not suffer from critical COVID-19 pneumonia

Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients

Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain

Neutralizing Autoantibodies to Type I Interferons

Convalescent Donor Plasma

Antibodies against type-I Interferon: detection and association with severe clinical outcome in COVID-19 patients

Diverse Functional Autoantibodies in Patients with COVID-19

Report a large auto-Ab screening that identified various targets in patients with severe COVID-19

Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19

Report that auto-Abs to type I IFNs impair type I IFN signaling in leukocytes at the single cell level in vivo

COVID-19 convalescent plasma composition and immunological effects in severe patients

Preexisting Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona

Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital

New-onset IgG autoantibodies in hospitalized patients with COVID-19

The interferon landscape along the respiratory tract impacts the severity of COVID-19

Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19

Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia

Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2

The first 12 months of COVID-19: a timeline of immunological insights

*Review of the immunological milestones since the onset of the COVID-19 pandemic

Interferon system deficiencies exacerbating severe pandemic virus infections

The human genetic determinism of life-threatening infectious diseases: genetic heterogeneity and physiological homogeneity?

Lethal Infectious Diseases as Inborn Errors of Immunity: Toward a Synthesis of the Germ and Genetic Theories

Impaired innate antiviral defenses in COVID-19: Causes, consequences and therapeutic opportunities

Life-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation

Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child